Apellis Pharmaceuticals, Inc.

Pharmaceutical Preparations·WALTHAM, MA·FY end 12/31·CIK 1492422

CEO Pay Ratio

2:1

CEO Total Comp

—

Median Employee

$330,094

Revenue

$1.0B

FY 2025

Net Income

$22.4M

FY 2025

Free Cash Flow

$45.0M

FY 2025

Net Margin

2.2%

Insider Net (180d)

-$1.5M

0 buys / 10 sales

CEO Pay Accountability

CEO comp as % of net income

—

Not enough data to compute.

CEO comp as % of buybacks

—

No buyback data for the most recent fiscal year.

5-year history · USD

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	Trend
Revenue	$1.0B	$781.4M	$396.6M	$75.4M	$66.6M
Gross Profit	—	—	—	—	—	—
Operating Income	$55.4M	-$165.0M	-$517.1M	-$594.6M	-$536.3M
Net Income	$22.4M	-$197.9M	-$528.6M	-$652.2M	-$746.4M
Operating CF	$45.3M	-$87.9M	-$594.7M	-$513.7M	-$563.1M
Capex	$313.0K	$403.0K	$773.0K	$1.5M	$1.1M
Free Cash Flow	$45.0M	-$88.3M	-$595.5M	-$515.3M	-$564.2M
Buybacks	—	—	—	—	—	—
Dividends	—	—	—	—	—	—

Gross Margin	—	—	—	—	—	—
Operating Margin	5.5%	-21.1%	-130.4%	-788.4%	-805.7%
Net Margin	2.2%	-25.3%	-133.3%	-864.7%	-1121.3%
FCF Margin	4.5%	-11.3%	-150.2%	-683.2%	-847.7%
R&D / Revenue	29.5%	41.9%	89.4%	513.4%	519.6%
Effective Tax	7.1%	-0.6%	-0.4%	-0.1%	-0.0%
Debt / Equity	—	—	0.48	0.55	—
Buybacks / FCF	—	—	—	—	—	—

FY 2024

Executive	Salary	Stock	Options	Bonus / Inc.	Other	Total
Adam TownsendChief Commercial Officer	$542.7K	$1.6M	$1.6M	$249.5K	$12.2K	$4.0M
Timothy SullivanChief Financial Officer	$531.0K	$1.6M	$1.6M	$242.7K	$23.8K	$3.9M
David Watson General Counsel	$513.1K	$1.6M	$1.6M	$211.1K	$15.9K	$3.9M